Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04266275 |
Other study ID # |
STUDY00000758 |
Secondary ID |
IRB00117251 |
Status |
Not yet recruiting |
Phase |
Phase 2
|
First received |
|
Last updated |
|
Start date |
November 2024 |
Est. completion date |
October 2026 |
Study information
Verified date |
April 2024 |
Source |
Emory University |
Contact |
Lisa Flowers, MD |
Phone |
404-251-8931 |
Email |
lflowe2[@]emory.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to see if curcumin can suppress HPV infection in women with
low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous
intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as
a potential medical treatment in HIV-uninfected and infected women with mild precancerous
lesions of the cervix or recently treated high-grade precancerous lesions at risk for
persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix
or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg
of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or
loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months
where they will undergo a Pap smear and HPV test to determine if there are higher rates of
HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal,
patients will then undergo colposcopic examination to evaluate cervical histology.
Description:
Cervical cancer is the third most common cancer worldwide. The causative agent responsible
for cervical cancer is the persistent infection with oncogenic Human Papillomavirus (HPV).
Rates of cervical cancer and HPV infection are increased particularly in HIV-infected women
due to immunosuppression with cervical cancer categorized as an AIDS-defining diagnosis.
Despite the promise of HPV vaccine in the prevention of cervical cancer, the widespread
availability of this vaccine is limited due to cost and accessibility. Therefore, prevention
strategies to reduce the risk of cervical cancer after HPV exposure entail treatment at the
premalignant state, including low-grade squamous intraepithelial lesions (LSIL) and
high-grade squamous intraepithelial lesions (HSIL), along with the eradication of HPV
infection. There is a desperate need for an inexpensive, non-invasive alternative method to
treat these premalignant cervical lesions and potentially suppress HPV infection.
Curcumin, an extract from turmeric, a popular culinary spice, has been used in traditional
Indian medicine for its anti-inflammatory and anti-infectious properties. Recent studies have
shown the potential effect of curcumin to reduce tumors and precancerous lesions in animal
and human cancer cells. It is postulated that curcumin achieves its effect on cancer cells by
modulating different cellular pathways as well as altering HPV effect on tissue cells.
The purpose of this study is to see if curcumin can suppress HPV infection in women with LSIL
disease or treated HSIL disease. The researchers plan to explore the effect of curcumin as a
potential medical treatment in HIV-uninfected and infected women with mild precancerous
lesions of the cervix or recently treated high-grade precancerous lesions at risk for
persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix
or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg
of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or
LEEP. They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV
test to determine if there are higher rates of HPV clearance after curcumin administration.
If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic
examination to evaluate cervical histology.